Author Guidelines

 Quick Start Guide

Please prepare the manuscript in Word according to the Instructions for Authors with graphics and tables integrated into the text, using the manuscript template available on the website:

Manuscripts must be submitted via: https://mc.manuscriptcentral.com/therapeuticsnow

File submission

The following items should be uploaded:

• Cover letter
  
• Manuscript main document: Please embed the tables/figures/schemes in the relevant positions
  
• Graphic files: original ChemDraw files and PNG, preferably in one zip file
  
• Graphical abstract: for the table of contents and the first manuscript page
  
• Supporting Information: as a separate file

Preparation of text

• Use the paragraph styles available within the template. Do not create new styles, and do not alter those that are preassigned.
  
• The Significance box must contain no more than 590 characters, including spaces.
  
• Use only one space after reference numbers, do not use tabs.
  
• Captions for graphic files should be given as part of the manuscript text, not as text within the graphic.
  
• Ensure that all graphics and tables are mentioned in the text.
  
• Avoid underlining and indentations.
  
• Follow further instructions as detailed in the manuscript template.

Tables

• Must be created in Word format.
  
• Place each item (paragraph, graphic, etc.) in its own cell.

Graphic files and photos

We accept JPG, PNG, and TIF files (not less than 300 dpi).

The graphical abstract must respect the following dimensions:

• Width 7.7 cm (3.0 in.)
  
• Height 6.4 cm (2.5 in.)

Acknowledgments should be brief and placed before the References

Funding Information should include all funding sources and funder grant/award numbers relevant to the manuscript.

References should be placed collectively after the Acknowledgment and numbered consecutively. Authors are encouraged to list all relevant references and cite extensively. Cited work that is unpublished at the moment of submission (“submitted”, “accepted for publication” or “in press”) must be provided as part of the “Supporting Information (for peer-review only)”. References to articles submitted to preprint servers (i.e. ChemRxiv) should be provided including the respective DOI. When one reference number contains more than one citation, please separate them into (a), (b), (c), etc. (see example 3). Provide the names and initials of all authors and do not use et al. Use journal abbreviations in accordance with Chemical Abstracts (Chemical Abstracts Source Index, CASSI). Please do not use tabs. Therapeutics NOW should be cited as follows: Therapeutics NOW year, volume, first page number.

Examples of References

(1)  New address: P. J. Kocienski, School of Chemistry, University of Leeds, Leeds LS2 9JT, UK.

(2)  Badart, M. P.; Hawkins, B. C. Synthesis 2021, 53, 1683.

(3)  (a) Majdecki, M.; Niedbała, P.; Jurczak, J. Chemistry- Select 2020, 5, 6424. (b) Majdecki, M.; Tyszka-Gumkowska, A.; Jurczak, J. Org. Lett. 2020, 22, 8687.(c) Majdecki, M.; Grodek, P.; Jurczak, J. J. Org. Chem.2021, 86, 995.

Conflicts of Interest

Therapeutics NOW takes conflicts of interest very seriously. You will be asked to declare your and your co-authors' potential conflicts of interest during the submission process. Failure to do so may incur serious delay!

Funding Under this heading, please specify whether and, if so, by whom the study and/or its publication was funded. If the study did not receive funding, please state verbatim in this section: “This research received no specific funding from public, commercial, or nonprofit entities.”

Statement of Ethics This journal adheres to rigorous ethical standards as outlined by the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE). Authors are expected to comply with these principles, particularly when reporting studies involving human or animal participants. All such studies must receive formal review and approval—or a waiver—from an appropriate Institutional Review Board (IRB) or ethics committee, and this must be clearly described in the Methods section, including the full name of the reviewing entity. For human studies, informed consent must be obtained in accordance with the principles of the Helsinki Declaration, and any necessary HIPAA consent should be documented. Authors must indicate whether individual consent was obtained or waived. Clinical trials must be registered in a public registry, with the registry name and number provided. For animal studies, approval from an Institutional Animal Care and Use Committee (IACUC) is required, and researchers must ensure humane treatment and justify the use of animals. 

Article Processing Charges

An article processing charge (APC) will be charged for every accepted manuscript published in Therapeutics NOW. It is currently 3015 EUR / 3355 USD excluding VAT.

An article will be published once payment has been received. You may want to contact your funder about covering these costs. Many grant-giving bodies have special funds reserved for APCs. Please note that there are no submission charges. If you have a submission voucher, no APC will be charged; instead, you will be asked to fill in the code number when asked for payment. Authors with insufficient funding might be eligible for a full or partial APC discount for publication in Therapeutics NOW.

The Editorial Office is happy to offer advice concerning all technical aspects of manuscript submission: TherapeuticsNOW@thieme.de

1 Editorial Policy

Therapeutics NOW is a high-quality, peer-reviewed journal dedicated to the publication of cutting-edge research in the field of innovative medical treatments and technologies. The journal serves as a platform for scientists, clinicians, and industry experts to share groundbreaking advancements in areas such as gene therapy, immunotherapy, drug discovery, and personalized medicine. Therapeutics NOW spans the scope of research from bench to bedside for results aimed at the development of next-generation therapeutics.

1.1 Journal Scope

Therapeutics NOW publishes a broad scope of research with diverse readerships, fostering interdisciplinary collaboration across chemistry, biology, bioengineering, and clinical sciences. The journal covers therapeutic research from the bench to the bedside, enabling translational impact and real-world relevance. Each article features a Research Significance Highlight to emphasize its contribution to therapeutic advancement.

To accelerate peer review and maintain high quality, the journal uses Select Crowd Review (SCR)—an innovative, anonymous crowd-sourced peer review process that engages a diverse pool of experts to enhance both speed and rigor of the review process.

Therapeutics NOW covers mainly but not exclusively the following areas of evidence-based research:

• Applied disease therapeutic research; molecular designs, nanomedicine, theranostics
  
• Small and large molecule therapeutics, including macromolecular compounds, nucleic acids, proteins, peptides and nucleotide therapeutics
  
• Gene therapy research
  
• Drug development for the treatment of common/tropical/infectious diseases
  
• Advances in instrument and method development in therapeutic-oriented chemistry and biology
  
• Chemistry and synthetic biology focusing on drug/treatment developments, includes prevention treatments e.g. vaccinations
  
• Bioengineering and biomaterials for therapeutic application
  
• Computational biology with applications to treatment programs
  
• Molecular and structural biology/biochemistry, e.g. cellular mechanisms, toxicology, specifically related to drugs or therapeutic programs
  
• Use of prediction tools such as AI in drug discovery and healthcare
  
• Industrial healthcare policies and solutions
  
• Drug-related translational studies
  
• Preclinical and phase 1 clinical trial results

1.2 Article Types

1.2.1 Original Articles Full reports of original research that provide dependable research results with detailed and repeatable experimental procedures and full characterization of all important new materials.

1.2.2 Reviews Review articles provide a comprehensive overview of a current topic, highlighting historical background/origins of a research area and cutting-edge contributions along with the most recent developments. They provide a concise assessment of the current state of the art and an outlook on future developments. Reviews should be up to 25 template-based pages, including tables and graphics.

1.2.3 Tutorial Reviews  serve as educational resources for researchers seeking to understand and apply emerging techniques, technologies, or interdisciplinary approaches within therapeutic science. These articles are designed to be accessible, instructive, and practically oriented, making them valuable to both early-career scientists and experienced researchers entering new areas of study.

1.2.4 Policy & Impact Brief these are short, analytically rich articles that examine the influence of healthcare policies, regulatory frameworks, and global health initiatives on the development, accessibility, and implementation of therapeutic innovations. These articles are written by people working in industry, academia, or governmental agencies.

1.2.5 Industrial Case Studies provide a real-world insights into the application of therapeutic science within industrial, clinical, or regulatory settings. These articles should document practical challenges, innovative solutions, and lessons learned from the development, optimization, or implementation of technologies or processes to develop to products. Contributions should emphasize the translational relevance of the work, showcasing how products were developed from basic research in Lab.. These articles are written by industrial and applied scientists to inform the readers about the latest challenges in their fields.

1.2.5 Perspective Article provide expert viewpoints on emerging trends, conceptual advances, unresolved challenges, or future directions in therapeutic science and global health. These contributions should stimulate scholarly discussion, provoke critical thinking, and inspire new lines of inquiry across disciplines. While these articles are not required to present original data, they should be grounded in current literature and reflect a high level of scholarly rigor. Authors are encouraged to articulate clear positions, support their arguments with relevant evidence, and propose actionable insights or hypotheses that may guide future research or policy. Perspective and Opinion pieces serve as a platform for thought leadership, fostering dialogue across the diverse communities engaged in therapeutic science from academia and industry to clinical practice and public health.

1.2.6 Translational Insight Discuss the pathway from fundamental scientific discovery to clinical implementation. These contributions should demonstrate how laboratory-based research evolves into therapeutic strategies, diagnostics, or interventions that directly impact patient care.

1.3 Journal Policy on Prior Publication

Thieme journals encourage the submission of papers that have been deposited in an initial draft version in preprint repositories such as ChemRxiv, arXiv, bioRxiv, Research Square, arXiv, and medRxiv. When posting to a preprint server, authors should retain copyright on their publication. Drafts of short conference abstracts or degree theses posted on the website of the degree-granting institution, and draft manuscripts deposited on authors’ or institutional websites are also welcome. All other prior publication is not acceptable.

During submission, authors should (1) note use of the preprint repository in the cover letter, (2) state what adjustments and/or updates the draft has undergone between deposition and submission and (3) cite the preprint, including the DOI, as a reference in the manuscript. The submitted manuscript (which is under review for publication in a journal) may be deposited on a preprint server at any time. Upon publication authors should add a link from the preprint to the published article.

1.4 Copyright All papers in Therapeutics NOW are published open access and are available online immediately upon publication without registration. Thieme publishes the papers under the terms of the Creative Commons Attribution (CC BY) 4.0 license, which permits any user to read, download, copy, distribute, and use the content for any lawful purpose. If other licenses are required, please contact OA-support@thieme.com.

1.5 Thieme’s general Journal Policies

Thieme has outlined its general policies regarding publication ethics and research integrity, including details about authorship and Contributorship, research involving animal and human subjects, research misconduct, our policy on prior publication, and much more. These can be found on our Journal Policies webpage (https://www.thieme.com/en-us/journal-policies).